Nasdaq apls.

The forecasts range from a low of 29.29 to a high of $99.75. The average price target represents an increase of 53.76% from its latest reported closing price of 43.31. See our leaderboard of ...9 de set. de 2023 ... Fintel reports that on September 8, 2023, B of A Securities maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral ...WALTHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...27 de set. de 2023 ... (APLS) Investors Affected by Stock Drop -- Levi & Korsinsky Pursuing Class Action Lawsuit ... (NASDAQ:APLS) investment and want to learn about a ...

Apellis Pharmaceuticals (APLS). Common Shares. Sell: $47.51|Buy: $48.04|Change: 1.73 (-3.50%).

That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ...Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.

WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...14 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price.25 сент. 2023 г. ... Apellis Pharmaceuticals (NASDAQ:APLS) announced Monday that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent ...hapabapa. Apellis Pharmaceuticals ( NASDAQ: APLS) won the FDA approval for its marketing application for lead asset pegcetacoplan on Friday as a treatment for geographic atrophy (GA) secondary to ...WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first ...

Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ...

Dec 4, 2023 · Apellis Pharmaceuticals Stock Down 1.9 %. Shares of NASDAQ:APLS opened at $60.40 on Monday. The company’s fifty day moving average price is $46.23 and its 200 day moving average price is $55.22.

Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM.WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022 at 4:30 p.m. ET. To access …Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 8563830 shares of its common stock at ...Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sunrun Inc (Symbol: RUN), where a ...Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing. Nov. 21. MT. Mizuho Raises Price Target on Apellis Pharmaceuticals to $49 …Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company and is a trending biotech stock to watch in the stock market as of late. This came after the company’s EMPAVELI ...Apellis Pharmaceuticals (NASDAQ: APLS) · Apellis Pharmaceuticals Return vs. S&P · Apellis Pharmaceuticals Company Info · News & Analysis · Financial Health ...

Records 1 - 18 of 20 ... Find the latest historical data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA ...Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week May 13. Consensus revenue estimates increase by 57%, …Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) andWe challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...Find the latest press releases from Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.

Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business highlights.

NASDAQ: APLS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Apellis Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. ... NASDAQ: Apellis Pharmaceuticals Inc Performance. USD USD; Diluted EPS (TTM)-5.23 …Apellis Pharmaceuticals ( NASDAQ: APLS) announced Tuesday that the company will reduce approximately 25% of its workforce in Q3 as part of a corporate restructuring initiative aimed at saving up ...Our analysis of options history for Apellis Pharmaceuticals APLS revealed 35 unusual trades. Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies ...Shares of APLS stock traded up $0.12 during trading hours on Monday, reaching $48.52. 498,084 shares of the company were exchanged, compared to its average volume of 2,676,809. Apellis ...How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors? CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business …WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...Shares of Apellis Pharmaceuticals Inc APLS declined following a report by Citron Research casting doubts on the company's prospects and the safety of its recently approved treatment for Geographic ...

WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights.

Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ...

USA. Published on June 4, 2021. venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately ...Shares of Apellis Pharmaceuticals ( APLS 6.66%) were down more than 9% on Wednesday, after falling as much as 12% earlier in the day. The company's shares fell following a short-seller report on ...Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ...WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …Feb 22, 2023 · With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ... WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...

It is now at its lowest level since June of 2020: 1. That is not a pretty 2-year chart, and investors are inevitably wondering whether the stock can be expected to recover anytime soon, or if it ...WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...... Pharmaceuticals (NASDAQ: APLS). Wedbush Analyst forecast on APLS. Laura ChicoWedbush. 08/29/23. $29.00. Hold. -40.94%. Downside. Reiterated. Follow. 0. 0.APLS | Complete Apellis Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Instagram:https://instagram. how to trade the spyatlanta braves stockscanopy growth stock forecast 2025exxon buy denbury Real time Apellis Pharmaceuticals (APLS) stock price quote, stock graph, news & analysis.Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) on December 1 and set a price target of $70.00. Yigal Nochomovitz’s Buy rating for ... wells fargo cash out refinance rates todaywhat is the best eye insurance Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ... ukraine etf Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ...Real time Apellis Pharmaceuticals (APLS) stock price quote, stock graph, news & analysis.LOS ANGELES, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) investors that a lawsuit filed on behalf of investors that purchased ...